Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.
CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.
The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.
CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.
The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.
CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.
Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.
CONMED Corporation (NYSE: CNMD) reported financial results for Q1 2022, with sales reaching $242.3 million, marking a 4.1% increase year over year. Domestic revenue rose 5.9%, while international revenue grew 2.2%. Diluted EPS was $0.47, up 51.6% from Q1 2021. The company raised its 2022 revenue guidance to between $1.105 billion and $1.150 billion, incorporating $20 million from the recent acquisition of In2Bones Global, subject to regulatory approval. Adjusted diluted EPS guidance is now $3.50 to $3.65.
CONMED Corporation (NYSE: CNMD) has announced a rescheduled date for its first quarter 2022 financial results due to a corporate conflict. The results will now be reported on May 4, 2022, after market close, instead of the previously scheduled April 27, 2022. A conference call will be held at 4:30 p.m. ET the same day. Updated dial-in information for the call is provided, and it will also be available via webcast. A replay will be accessible from 7:30 p.m. ET on May 4 to 11:59 p.m. ET on May 18.
CONMED Corporation (NYSE: CNMD) will announce its financial results for Q1 2022 on
CONMED Corporation (NYSE: CNMD) announced its Annual Meeting of Stockholders will take place virtually on May 25, 2022, at 1:30 p.m. ET. Shareholders on record as of April 5, 2022 can vote. Detailed participation instructions will be provided in the proxy statement to be filed on April 15, 2022, available on the company's website. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q4 and full year 2021. Q4 sales reached $274.0 million, an increase of 8.4% year-over-year. Domestic revenue rose 5.0% while international sales surged 12.7%. Q4 diluted EPS stood at $0.75, down from $0.81 in 2020, yet adjusted EPS rose to $1.07 from $0.84. For 2021, total sales hit $1.01 billion, a 17.2% increase. The company anticipates 2022 revenue of $1.075 billion to $1.125 billion and adjusted EPS between $3.60 and $3.85.
CONMED Corporation (NYSE: CNMD) will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 9:00 a.m. ET. The presentation will feature Curt R. Hartman, Chair of the Board, President & CEO, and Todd W. Garner, Executive Vice President and CFO. Investors can access a live webcast through the Company’s website, with a replay available afterward. CONMED is a medical technology company providing surgical devices for minimally invasive procedures across various specialties.
CONMED Corporation (NYSE:CNMD) will announce its fourth-quarter 2021 financial results after market close on January 26, 2022. The company's management will host a conference call at 4:30 p.m. ET the same day to discuss these results. Interested participants can join the call via phone or webcast through CONMED's website. A recording will be available for a week following the call. The company focuses on surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED Corporation (NYSE: CNMD) has announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded fireside chat featuring Chair and CEO Curt R. Hartman and CFO Todd W. Garner will be available from 10:00 a.m. ET on November 22 until December 2, 2021, for registered attendees. Additionally, the chat can be replayed on the Company’s website starting November 22 at 10 a.m. ET. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
FAQ
What is the current stock price of CONMED Corporation (CNMD)?
What is the market cap of CONMED Corporation (CNMD)?
What does CONMED Corporation specialize in?
Where is CONMED Corporation headquartered?
How many employees does CONMED Corporation have?
What are the main product specialties of CONMED Corporation?
What are the primary reporting units of CONMED Corporation?
In which regions does CONMED Corporation generate most of its revenue?
What is the mission of CONMED Corporation?
How does CONMED Corporation ensure customer and patient satisfaction?
What recent achievements has CONMED Corporation made?
What is CONMED Corporation's approach to innovation?
